

Chemotherapy-Induced Nausea and Vomiting: Prevention, Detection, and Treatment—How Are We Doing?

A continuing medical education activity sponsored by the Academy for Healthcare Education.

Release Date: January 1, 2004 • Expiration Date: January 31, 2005

TARGET AUDIENCE

The target audience for this educational activity is medical oncologists.

NEEDS STATEMENT

Chemotherapy-induced nausea and vomiting (CINV) is a commonly encountered adverse reaction associated with the use of chemotherapy. This continuing medical education (CME) activity is designed to provide practicing oncologists with current information related to the prevention, detection, and treatment of CINV. The CME activity begins with a review of current incidence and prevalence data and the associated important implications for caregivers and patients. A basic science review of CINV etiology and pathophysiology follows the first section. Next, approaches to risk stratification, patient assessment, and monitoring are presented. The activity concludes with a presentation of treatment class effects, individual agent efficacy, and key treatment recommendations by several leading professional associations.

LEARNING OBJECTIVES

After reading this educational journal supplement, medical oncologists should be better able to:

- Define types of chemotherapy-induced nausea and vomiting (CINV) and describe the epidemiology and causative factors for CINV
- Discuss central clinical and health-related quality-of-life implications of CINV
- Describe approaches to patient risk stratification, assessment, and symptom monitoring
- Discuss antiemetic treatment class effects and the efficacy of specific agents
- Review CINV clinical practice guidelines developed by leading professional associations

DISCLOSURE

In compliance with the *Standards for Commercial Support of Continuing Medical Education* of the Accreditation Council for Continuing Medical Education, the Academy for Healthcare Education (Academy) informs CME participants of any significant financial interest or other relationship a faculty member or the Academy has with the manufacturer(s) of any commercial product(s) discussed in the CME activity. In addition, faculty are expected to disclose discussion of unlabeled uses of commercial products or investigational uses not yet approved for any purpose.

Unrestricted educational grants to the Academy from GlaxoSmithKline.

Dr. Grunberg has received grants/research support from Aventis, GlaxoSmithKline, and Merck. He is a consultant for Aventis, GlaxoSmithKline, Merck, MGI Pharma, and Roche. He is also on the Speakers' Bureau for GlaxoSmithKline, Merck, and MGI Pharma.

ACCREDITATION



The Academy for Healthcare Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA PRA CATEGORY 1 CREDIT

The Academy for Healthcare Education designates this educational activity for a maximum of 1 category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

In order to receive a statement of credit, participants must successfully complete the post test and activity evaluation after reviewing the activity materials. Participants will have two opportunities to pass the post test with a score of 80% or higher. The instructions for receiving a CME certificate of participation are located at the end of this activity with the post test.

This educational activity is offered as both a journal supplement with the January/February 2004 issue of *The Journal of Supportive Oncology* and the April 2004 issue of *Oncology Special Edition*. Please submit from only one activity for AMA PRA credit. Dual certificates are not available.

DISCLAIMER

The opinions expressed in this publication are those of the participating faculty and not those of the Academy for Healthcare Education, GlaxoSmithKline, or any manufacturers of products mentioned herein. This journal supplement, *Chemotherapy-Induced Nausea and Vomiting: Prevention, Detection, and Treatment—How Are We Doing?*, may include reference to off-label/unapproved uses of drugs. Participants are encouraged to consult the package inserts for updated information and changes regarding indications, dosages, and contraindications, particularly for new or infrequently used products.

This educational activity is supported by an unrestricted educational grant from GlaxoSmithKline.



Copyright © 2004 by BioLink Communications, Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

The Journal of Supportive Oncology (ISSN 1544-6794) is published bimonthly by BioLink Communications, Inc., 26 Cedar Drive, Huntington, NY 11743. BPA membership applied for May 2003.

Statements and/or opinions expressed in the reports and communications contained herein are those of the authors and not necessarily those of the editors, editorial staff, publisher, or publishing staff of BioLink Communications, Inc., or of GlaxoSmithKline. The editors, editorial staff, publisher, publishing staff, and GlaxoSmithKline assume no, and disclaim any, responsibility or liability for such material. While every effort has been made to ensure the accuracy of the information presented herein, readers are advised to exercise clinical judgment in assessing the applicability of this information to their own clinical practice and patient population. In addition, readers are cautioned to refer to the manufacturer's official package labeling before prescribing or administering any drug or diagnostic product mentioned. Neither the editors nor publisher can take responsibility for the statements and opinions expressed by the researchers and clinicians whose work is quoted herein.